Matching within a hybrid RCT/RWD : framework on associated causal estimands
As the regulatory environment becomes progressively receptive toward utilizing real-world evidence, a spectrum of real-world data incorporation techniques in trial conduct and analysis has seen increasing interest and adoption in different stages of drug development. Of particular interest is leveraging external control data to augment the control arm in a concurrent randomized controlled trial, where patients are enrolled in both investigational treatment arm and the control arm. Yet despite the emerging literature in external data borrowing in a hybrid trial setting, very little discussion focuses on delineating what should be matched and what is actually being estimated, especially when a variety of matching schemes can be considered. In general, external control can be matched in four different ways: (1) matching with the intersection between investigational treatment and concurrent control, (2) matching with the union of concurrent investigational treatment and concurrent control, (3) matching with concurrent control alone, and (4) matching with investigational treatment alone. In this article, the formulation of estimands for different matching schemes are detailed to describe what these matching methods facilitate to answer. Simulation studies are also conducted to evaluate the performance characteristics under different matching schemes, estimation methods, effect size assumptions, and missingness of confounders.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Journal of biopharmaceutical statistics - 33(2023), 4 vom: 04. Juli, Seite 439-451 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lin, Junjing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Augmented control |
|---|
| Anmerkungen: |
Date Completed 26.06.2023 Date Revised 26.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10543406.2022.2105346 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344494543 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344494543 | ||
| 003 | DE-627 | ||
| 005 | 20231226022911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10543406.2022.2105346 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344494543 | ||
| 035 | |a (NLM)35929973 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lin, Junjing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Matching within a hybrid RCT/RWD |b framework on associated causal estimands |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.06.2023 | ||
| 500 | |a Date Revised 26.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a As the regulatory environment becomes progressively receptive toward utilizing real-world evidence, a spectrum of real-world data incorporation techniques in trial conduct and analysis has seen increasing interest and adoption in different stages of drug development. Of particular interest is leveraging external control data to augment the control arm in a concurrent randomized controlled trial, where patients are enrolled in both investigational treatment arm and the control arm. Yet despite the emerging literature in external data borrowing in a hybrid trial setting, very little discussion focuses on delineating what should be matched and what is actually being estimated, especially when a variety of matching schemes can be considered. In general, external control can be matched in four different ways: (1) matching with the intersection between investigational treatment and concurrent control, (2) matching with the union of concurrent investigational treatment and concurrent control, (3) matching with concurrent control alone, and (4) matching with investigational treatment alone. In this article, the formulation of estimands for different matching schemes are detailed to describe what these matching methods facilitate to answer. Simulation studies are also conducted to evaluate the performance characteristics under different matching schemes, estimation methods, effect size assumptions, and missingness of confounders | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Estimand | |
| 650 | 4 | |a augmented control | |
| 650 | 4 | |a causal inference | |
| 650 | 4 | |a matching | |
| 650 | 4 | |a multiple treatment propensity score | |
| 650 | 4 | |a real-world evidence | |
| 700 | 1 | |a Yu, Guanglei |e verfasserin |4 aut | |
| 700 | 1 | |a Gamalo, Margaret |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biopharmaceutical statistics |d 1991 |g 33(2023), 4 vom: 04. Juli, Seite 439-451 |w (DE-627)NLM012811432 |x 1520-5711 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:4 |g day:04 |g month:07 |g pages:439-451 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10543406.2022.2105346 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 4 |b 04 |c 07 |h 439-451 | ||